rmdopen.bmj3d
Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus
Objectives Cardiovascular disease is a leading cause of mortality in systemic lupus erythematosus (SLE). Frailty has been ...
rmdopen.bmj1d
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Objectives The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) ...
rmdopen.bmj3d
Anifrolumab: the new frontier in the treatment of genetic interferonopathies
Understanding the precise mechanisms of monogenic autoinflammatory diseases provides crucial insights into the complex pathophysiology of more common multifactorial diseases, while treatments ...
rmdopen.bmj3d
Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
Objectives Most studies on difficult-to-treat rheumatoid arthritis (D2T RA) have focused on established RA. Here, we analyse whether disease activity in the early stages of RA could influence ...
rmdopen.bmj6d
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...
rmdopen.bmj4d
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical ...
rmdopen.bmj5d
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
We will not keep your email address; we ask for it so your friend knows the email isn't spam.
rmdopen.bmj5d
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
Background The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an ...